NA Selank Amidate

NA Selank Amidate exhibits improved molecular stability and in vivo pharmacokinetic profile through a double-modification strategy of N-terminal acetylation and C-terminal amidation based on the original structure of Selank.

 

SKU: 198884 קאַטעגאָריע:
ייַנטיילן דיין ליבע

NA Selank Amidate exhibits improved molecular stability and in vivo pharmacokinetic profile through a double-modification strategy of N-terminal acetylation and C-terminal amidation based on the original structure of סעלאַנק.

This results in an increased half-life, ימפּרוווד בלוט-מאַרך שלאַבאַן penetration efficiency, and prolonged bioactivity in both molecular and animal models.

דערצו, NA Selank Amidate exhibits potent יממונאָמאָדולאַטיאָן and anti-stress activity.

סיקוואַנס

ac-thr-lys-pro-arg-pro-gly-pro-nh2

CAS נומער

/

מאָלעקולאַר פאָרמולע

C35H60N12O9

מאָלעקולאַר וואָג

792.94

Research Of NA Selank Amidate

1.Retained and Enhanced Efficacy

Efficacy-wise,NA Selank Amidate retains all of the characteristics of Selank, רעגיאַלייטינג gamma-aminobutyric acid (GABA) neurotransmission in the brain while also modulating the dopaminergic און serotonergic systems to deliver outstanding anxiolytic און antidepressant effects.

It also shows better efficacy than Selank in enhancing cognitive and neuroprotective functions, producing pronounced positive effects on learning, memory, and attention.

2.Anxiolytic and Mood-Stabilizing Effects

In a concentration-dependent and subtype-selective manner, NA Selank Amidate allosterically modulates the GABA-A receptor by potentiating the binding efficacy of GABA to its receptor or enhancing chloride ion channel opening efficiency.

This significantly increases the inhibitory tone in key brain circuits, producing marked anxiolytic effects.

דערצו, the side effects of this anxiolytic action are significantly milder than those of conventional anxiolytic drugs, making NA Selank Amidate a more attractive mood-stabilizing compound.

3.Cognitive Enhancement and Neuroprotection

NA Selank Amidate directly activates BDNF gene transcription by inducing פאָספאָרילאַטיאָן of the promoter-located CREB transcription factor and acetylation of histone H3, increasing BDNF mRNA levels 3.2-fold in hippocampal dentate gyrus granule cells and prefrontal cortical pyramidal neurons and protein secretion 2.8-fold within 24 שעה.

This activates the TrkB receptor signaling pathway downstream, inducing the Ras-MAPK and PI3K-אקט cascade to increase dendritic spine density by 39%, upregulate synaptophysin expression by 45%, and restore LTP amplitude to baseline.

This successfully prevents stress-induced hippocampal neuronal injury and cognitive decline, demonstrating distinct neuroprotective properties.

4.Immunomodulatory and Anti-Stress Effects

NA Selank Amidate is a competitive inhibitor of enkephalin-degrading enzyme, protecting endogenous opioid peptides from hydrolysis and thereby elevating their levels, while it inhibits לפּס (lipopolysaccharide)-induced expression of pro-inflammatory סיטאָקינז כולל IL-6 און TNF-α by 40–60% in astrocytes.

NA Selank Amidate also represses NF-κB nuclear translocation by interfering with the recruitment of MyD88 adaptor protein, providing protective regulation in the neuroinflammatory microenvironment.

COA

HPLC

MS

(1) Doyno, ג. ר.; ווייַס, ג. מ. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol 2021, 61 Suppl 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Kasian, א.; Kolomin, טי.; אַנדרעעוואַ, ל.; Bondarenko, E.; מיאַסאָעדאָוו, נ.; Slominsky, פּ.; Shadrina, מ. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol 2017, 2017, 50910

(3) Kolik, ל. ג.; Nadorova, א. V.; Antipova, טי. א.; Kruglov, ש. V.; קודרין, V. ש.; Durnev, א. ד. סעלאַנק, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex

(4) Kolik, ל. ג.; Nadorova, א. V.; Seredenin, ש. ב. Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice. בולל עקספּ ביאָל מעד 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 From NLM Medline.

(5) קאָסטן, נ. V.; סאָקאָלאָוו, אָ.; Gabaeva, מ. V.; גריווענניקאָוו, איך. א.; אַנדרעעוואַ, ל. א.; מיאַסאָעדאָוו, נ. פ.; זוזוליאַ, א. א. [סעמאַקס און סעלאַנק ינכיבאַט די ענקעפאַלין-דיגריידינג ענזימעס פון מענטש סערום]]. ביאורג כים 2001, 27 (3), 180-183. DOI: 10.1023/א:10113730028

(6) Neznamov, ג. ג.; Teleshova, E. ש.; Bochkarev, V. ק.; Koschelev, V. V.; Syunyakov, טי. ש. P.3.036 Novel anxiolytic Selank: Results of thePhase II clinical trials. European Neuropsychopharmacology 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Slominsky, פּ. א.; Shadrina, מ. איך.; Kolomin, טי. א.; Stavrovskaya, א. V.; Filatova, E. V.; אַנדרעעוואַ, ל. א.; Illarioshkin, ש. נ.; מיאַסאָעדאָוו, נ. פ. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sc

(8) Sollertinskaja, טי. נ.; Shorochov, מ. V.; מיאַסאָעדאָוו, נ. פ. The cerebroprotective effects of Semax and Selank in primates at different types of neurosis. International Journal of Psychophysiology 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

סיקוואַנס:

ac-thr-lys-pro-arg-pro-gly-pro-nh2

CAS:

/

מ.וו:

792.94 ג / מאָל

היים זוכן ווהאַצאַפּפּ סערוויסעס פּראָדוקט